Spotlight -

B + L Dry Eye Series|

Transforming Glaucoma Management|

Zeiss Clinical Cases

Viewing

News|Articles|November 8, 2018

CATARACT SURGERIES IN CHALLENGING CASES: Choosing the CT LUCIA 621P IOL to optimize success in eyes with compromised zonules

Author(s)Andreas F. Borkenstein, MD

DOWNLOAD THE CASE STUDY

Newsletter

Don’t miss out—get OT Europe updates delivered straight to your inbox.

Latest CME

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH

MacTel Decoded: Rethinking Conventional Approaches With Novel Neuroprotective Strategies

MacTel Decoded: Rethinking Conventional Approaches With Novel Neuroprotective Strategies

Charles C. Wykoff MD, PhD; Diana V. Do, MD; Dante Pieramici, MD, FASRS; Jed H. Assam, MD, MS

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Treatment Optimization in the Evolving Anti-VEGF Era

Treatment Optimization in the Evolving Anti-VEGF Era

Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Dilsher S. Dhoot, MD, FASRS

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Deep Parikh, MD

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Damon Dierker, OD FAAO; Maria Pribis, OD

(COPE Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

(COPE Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

Mary Qiu, MD; Paul Singh, MD; Danica J. Marrelli, OD, FAAO

(CME Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

(CME Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

Rahul Tonk, MD; Jade Coats, OD, FAAO; Aaleya Koreishi, MD; Zeba Syed, MD

(COPE Track) Reducing Treatment Burden in Retinal Disease Care With Extended-Duration Anti-VEGF Therapies

(COPE Track) Reducing Treatment Burden in Retinal Disease Care With Extended-Duration Anti-VEGF Therapies

John Kitchens, MD

(CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

(CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

Geeta Lalwani, MD; Alla Goldberg, MD; Elite Bor-Shavit, MD

Trending on Eye Care Network - Ophthalmology Times

FDA requires NAION warning across the GLP-1 receptor agonist class

Anti-VEGF switches for persistent fluid: A review of 3 clinical cases

City Therapeutics doses first participant in phase 1 trial of RNAi therapy CITY-RBP4 for Stargardt disease

Inflammasome inhibition with K8 in geographic atrophy: A Q&A

Tenpoint Therapeutics opens telehealth access to Yuvezzi for adults with presbyopia